Aerovate Therapeutics (Aerovate Therapeutics) Cash-to-Debt : 128.34 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aerovate Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 128.34.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aerovate Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Aerovate Therapeutics's Cash-to-Debt or its related term are showing as below:

AVTE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.41 Med: 175.55 Max: No Debt
Current: 128.34

During the past 5 years, Aerovate Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.41. And the median was 175.55.

AVTE's Cash-to-Debt is ranked better than
80.56% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs AVTE: 128.34

Aerovate Therapeutics Cash-to-Debt Historical Data

The historical data trend for Aerovate Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aerovate Therapeutics Cash-to-Debt Chart

Aerovate Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.41

No Debt

291.59

118.55

181.39

Aerovate Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													123.37	175.55	167.12	181.39	128.34

Competitive Comparison of Aerovate Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Aerovate Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerovate Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's Cash-to-Debt falls into.

Aerovate Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aerovate Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	122.439	/	(0.42	+	0.255)
	=	181.39

Aerovate Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	99.334	/	(0.445	+	0.329)
	=	128.34

Aerovate Therapeutics (NAS:AVTE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aerovate Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerovate Therapeutics (Aerovate Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

930 Winter Street, Suite M-500, Waltham, MA, USA, 02451

Website

https://www.aerovatetx.com

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

Executives

Hunter Gillies	officer: Chief Medical Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Ralph Niven	officer: Chief Development Officer	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Benjamin T Dake	officer: See Remarks	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Marinus Verwijs	officer: SENIOR VICE PRESIDENT, CMC	C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes	director, officer: Chief Executive Officer	1365 MAIN STREET, WALTHAM MA 02451
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot	officer: Chief Commercial Officer	AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel	director	4362 24TH STREET, SAN FRANCISCO CA 94114
George A Eldridge	officer: See Remarks	C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Allison Dorval	director	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Maha Katabi	director, 10 percent owner	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116